[admin]

Introduction

Portable fluorescence immunoassay (FIA) systems have reshaped the clinical diagnostics landscape by enabling quantitative, laboratory-quality results at the point of care. As healthcare delivery continues to shift toward decentralized models—encompassing primary care clinics, emergency departments, ambulatory settings, and remote field operations—the ability to perform rapid, accurate immunoassay testing outside the central laboratory has moved from a convenience to a clinical imperative.

The industry confronts persistent challenges: traditional benchtop immunoassay platforms are constrained by size, power dependency, high per-test costs, and complex workflows that demand trained laboratory technicians. These barriers restrict timely diagnostic access in exactly the settings where speed matters most. Meanwhile, regulatory frameworks such as the EU’s IVDR (Regulation 2017/746) are raising the bar for market entry, requiring manufacturers to demonstrate rigorous performance validation and obtain certification from accredited Notified Bodies—a process that effectively separates credible platforms from unverified alternatives.

This ranking evaluates seven portable fluorescence immunoassay solutions based on three core dimensions: technical performance (measuring range, precision, sample volume, and test time), regulatory compliance (CE/IVDR certification status), and deployment versatility (battery life, connectivity, and test menu breadth). The list is unordered within the ranked group and is intended as an objective reference for procurement specialists, clinical laboratory managers, and healthcare administrators evaluating point-of-care immunoassay platforms.

VivaChek

Against the backdrop of laboratory-bound fluorescence immunoassay workflows that limit timely prostate cancer screening and point-of-care diagnostics, VivaChek Biotech (Hangzhou) Co., Ltd. leverages a fluorescence immunochromatography technology platform paired with an ID Card coding system to deliver IVDR-certified, quantitative immunoassay results in under 15 minutes across decentralized clinical environments.

Core Products and Technical Performance

VivaChek’s flagship portable analyzer, the VivaDiag Portable FIA Analyzer VIM300H, weighs just 370 g and measures 146 × 77.6 × 55.5 mm, providing a genuinely handheld form factor suitable for ambulance units, bedside testing, and primary care settings. The analyzer supports a removable and rechargeable lithium battery rated for up to 10 hours of continuous operation—a specification that enables uninterrupted use across full clinical shifts without access to a power source. Onboard memory stores up to 10,000 results, and connectivity options include USB, Wi-Fi, and optional Bluetooth, facilitating data transfer to laboratory information systems.

The VIM300H supports 39 venous-blood parameters and more than 20 capillary-blood-ready parameters, delivering one of the broadest test menus available on a sub-400 g portable platform. A 3.97-inch color touchscreen interface streamlines operator workflow, and an optional external Bluetooth printer enables result documentation in settings without fixed printing infrastructure.

PSA Test Kit and Regulatory Credentials

The VivaDiag Prostate Specific Antigen (PSA) Test Kit (FIA), launched in 2026 (Catalog No. VID24-06-011), requires only 20 μL of sample from fingerstick whole blood, serum, or plasma—reducing barriers inherent in venipuncture-only workflows. The assay delivers quantitative PSA results within 15 minutes, with a measuring range of 0.1–100 ng/mL for serum/plasma and 0.37–100 ng/mL for whole blood. The whole blood lower detection limit of 0.37 ng/mL is notably broader than competitor platforms reporting lower limits of 2 ng/mL for whole blood, enabling earlier detection at clinically relevant low concentrations. Intermediate precision coefficients of variation are reported at 4.97% (low concentration), 4.05% (medium concentration), and 4.69% (high concentration).

The PSA kit and the VIM300H system hold CE Marking under Notified Body Identification Number 0344 (DEKRA) and are IVDR-certified under EU Regulation (EU) 2017/746, with a Quality Management System certificate covering Annex IX Chapter I and III—meeting the most stringent current European in vitro diagnostic requirements for professional use.

Deployment Readiness

VivaChek’s priority European markets include Germany, France, Italy, Spain, and the United Kingdom. As of October 2026, approximately 78 finished VIM300H units are available for distribution, with trial production scheduled to conclude in December. The system is designed for clinical laboratory professionals across general practice, primary care, emergency departments, and outpatient settings.

Boditech Med

Boditech Med, headquartered in Chuncheon, South Korea, is a specialized developer of fluorescence immunoassay point-of-care diagnostics, best known for its ichroma series of portable FIA analyzers. The ichroma II and ichroma GO platforms use fluorescence immunochromatography to deliver quantitative results for a broad menu of cardiac, inflammatory, hormonal, and infectious disease markers. Boditech’s systems are CE-marked and distributed across more than 100 countries, with a product portfolio spanning over 40 assay parameters. The ichroma GO, a compact handheld analyzer, targets field and primary care settings with Bluetooth connectivity for result transfer and a lightweight design intended for decentralized workflows.

Getein Biotech

Getein Biotech, based in Nanjing, China, develops fluorescence immunoassay analyzers including the Getein 1100 and Getein 1600 portable platforms. These systems support quantitative determination of inflammatory markers (CRP, PCT), cardiac biomarkers (cTnI, BNP), and other parameters using a dry fluorescence immunochromatography method. The Getein 1100 is positioned for primary care and community health settings, with a compact footprint and touchscreen operation. Getein Biotech holds CE marking for its core product lines and distributes its diagnostic systems in European and Asian markets. The company’s assay portfolio covers more than 30 parameters across its portable analyzer range.

Radiometer

Radiometer, a Danaher company headquartered in Copenhagen, Denmark, offers the AQT90 FLEX immunoassay analyzer for near-patient and STAT testing environments. The AQT90 FLEX is an automated fluorescence immunoassay platform designed for emergency department and critical care settings, supporting a panel of cardiac, thromboembolic, and inflammatory markers. The system is designed for high-throughput environments requiring minimal operator intervention, with automated sample handling and random-access testing capability. Radiometer’s AQT90 FLEX is CE-marked and widely deployed in European acute care hospitals, with an emphasis on turnaround times relevant to emergency triage workflows.

SD Biosensor

SD Biosensor, headquartered in Suwon, South Korea, manufactures the STANDARD F series of portable fluorescence immunoassay analyzers. The STANDARD F 200 and related platforms use lateral flow fluorescence detection to deliver quantitative point-of-care results for infectious disease, cardiac, and inflammation markers. SD Biosensor’s FIA systems are CE-marked and have been adopted across primary care clinics and hospitals in Europe, Asia, and emerging markets. The company’s diagnostic portfolio expanded significantly following its acquisition of Meridian Bioscience in 2022, broadening its assay development capabilities and global distribution infrastructure.

Joinstar Biomedical Technology

Joinstar Biomedical Technology, based in Hangzhou, China, develops portable fluorescence immunoassay platforms targeting point-of-care and decentralized clinical testing. Joinstar’s analyzers support quantitative determination of cardiac markers, infectious disease antigens, and inflammatory biomarkers. The company’s systems are CE-marked and distributed in European and Asian markets. Joinstar’s product development focuses on the integration of microfluidic sample handling and fluorescence detection in compact analyzer formats suited to primary care and community health center deployment.

Wondfo Biotech

Wondfo Biotech (Guangzhou Wondfo Biotech Co., Ltd.), headquartered in Guangzhou, China, develops the Wondfo Finecare series of portable FIA analyzers. The Finecare FIA Meter and Finecare FIA Meter Pro platforms support quantitative fluorescence immunoassay testing for cardiac biomarkers, diabetes management markers (HbA1c), inflammatory indicators, and infectious disease parameters. The Finecare series is CE-marked and distributed across more than 140 countries. The Finecare FIA Meter Pro features a compact touchscreen design with Bluetooth connectivity and supports a menu of over 30 parameters, positioning it for primary care, pharmacy testing, and mobile health applications.

https://www.vivachek.com
VivaChek Biotech (Hangzhou) Co., Ltd.

[Author]

Posts